FDA grants clearance of OcuMet Beacon, a noninvasive tool for assessing retinal health

News
Article

The company said it will be available on the US market for use in clinics and healthcare institutions.

Eye being scanned Image credit: AdobeStock/АннаКовальчук

OcuMet Beacon is indicated for ophthalmoscope scanning for infrared and autofluorescence imaging of a human retina with or without the use of a mydriatic agent. Image credit: AdobeStock/АннаКовальчук

The US Food and Drug Administration (FDA) has granted clearance for OcuSciences, Inc.’s flagship device OcuMet Beacon, the company announced in a press release.1 The company said it will soon be available on the US market for use in clinics and healthcare institutions across the United States.

OcuMet Beacon is a tool for assessing retinal health. Capturing a naturally occuring fluorescence from the eye using proprietary illumination and detection technology, OcuMet Beacon is indicated for ophthalmoscope scanning for infrared (IR) and autofluorescence (AF) imaging of a human retina with or without the use of a mydriatic agent. The technology of the OcuMet Beacon is noninvasive, requiring no injections, dyes, or physical contact with the eye.

“With our collaborators, we are extending the depth of understanding for retinal diseases,” said Kurt Riegger, chief executive officer of OcuSciences. “This is a game-changer for the many patients and ophthalmologists who stand to benefit from more precise and deeper insight.”1

The safety and clinical utility of the OcuMet Beacon is demonstrated and documented in an extensive set of peer reviewed clinical studies and a dozen new studies to be presented at ARVO, expanding the clinical use of the tool.

For more information about the OcuMet Beacon, visit www.ocusciences.com .

References:
1. OcuSciences announces FDA marketing clearance of OcuMet Beacon in retinal health assessment at ARVO. Published May 1, 2025. Accessed May 1, 2025. https://www.businesswire.com/news/home/20250501118944/en/OcuSciences-Announces-FDA-Marketing-Clearance-of-OcuMet-Beacon-in-Retinal-Health-Assessment-at-ARVO?

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Rhue and Canto-Sims talk the value of contact lens patients, financial insights, and key benefits of implementing a contact lens management system.
Drs Brianna Rhue and Diana Canto-Sims discuss the benefits of implementing a contact lens management system that can help improve lens sales at your practice.
Matt Jones, OD; Matt Burns, OD; and Joe Sugg, OD; detailed what optometrists can expect to change when HB 1353's regulations are enacted later this year.
Dana Shannon, OD, FAAO, shares pearls on spotting red flags in need of referral and enhancing patient care with follow-up compliance.
Dana Shannon, OD, FAAO, detailed a lecture she gave at the NOA Midwestern Symposium earlier this month.
CRU 2025 provided the latest insights regarding glaucoma, dry eye disease, retina, myopia, neurotrophic keratitis, and keratoconus.
Rachelle Lin, OD, MS, FAAO
Melissa Barnett, OD, FAAO, FSLS, FBCLA, gave 2 presentations alongside other ODs and MDs at CRU 2025.
Rachelle Lin, OD, MS, FAAO, at CRU Eye Symposium 2025
Melissa Tawa, OD, FAAO, provides insights to take glaucoma management from reactive to proactive in presentations given at CRU 2025 in Napa, California.
© 2025 MJH Life Sciences

All rights reserved.